Investor's Business Daily on MSN
Here's why this colon cancer testing biotech is a mutual fund favorite
This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies ...
Guardant Health (GH) stock gains as RBC Capital Markets initiates at Outperform with a $185 target, citing catalysts and ...
Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer ...
By Nancy Lapid May 27 (Reuters) - People who skip colorectal cancer screening because colonoscopy or stool testing seems too burdensome now have a blood test option from Guardant Health among ...
Guardant Health is touting the results of a new study showing its Reveal blood test can detect whether chemotherapy is failing months before evidence shows up on regular scans, allowing oncologists to ...
Dr. McDreamy has signed onto yet another cancer awareness initiative. “Grey’s Anatomy” star Patrick Dempsey, who has worked with Amgen since 2007 and joined forces with Pfizer in 2024, is now ...
PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results